Carroll Financial Associates’s Pacira BioSciences PCRX Stock Holding History

Carroll Financial Associates’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$9K	Hold	150	–	–	﹤0.01%	1201
2021 Q3	$8K	Hold	150	–	–	﹤0.01%	1281
2021 Q2	$9K	Hold	150	–	–	﹤0.01%	1322
2021 Q1	$10K	Hold	150	–	–	﹤0.01%	1215
2020 Q4	$8K	Hold	150	–	–	﹤0.01%	1172
2020 Q3	$9K	Hold	150	–	–	﹤0.01%	1071
2020 Q2	$7K	Hold	150	–	–	﹤0.01%	1125
2020 Q1	$5K	Hold	150	–	–	﹤0.01%	1136
2019 Q4	$6K	Hold	150	–	–	﹤0.01%	1212
2019 Q3	$5K	Hold	150	–	–	﹤0.01%	1192
2019 Q2	$6K	Hold	150	–	–	﹤0.01%	1158
2019 Q1	$5K	Hold	150	–	–	﹤0.01%	1106
2018 Q4	$5K	Buy	+150	New	+$7K	﹤0.01%	1031

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Carroll Financial Associates's PCRX Position: Q4 2021 in Review

Carroll Financial Associates held its Pacira BioSciences (PCRX) position steady in Q4 2021 at 150 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

Carroll Financial Associates first reported a position in PCRX in Q4 2018 and has held it in 13 quarters since. The position peaked at $10K in Q1 2021. 276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

Carroll Financial Associates held 150 shares of Pacira BioSciences worth $9K as of Q4 2021.
Carroll Financial Associates left its Pacira BioSciences share count unchanged in Q4 2021.
Pacira BioSciences made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1201 holding.
Carroll Financial Associates first reported a position in Pacira BioSciences in Q4 2018 and has held it in 13 quarters since.
Carroll Financial Associates's Pacira BioSciences position peaked at $10K in Q1 2021.
276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.